Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.W | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > CNN

<< Previous

Bullboard Posts

Next >>

Comment by jewel9mon Feb 15, 2023 8:37pm

151 Views

Post# 35288814

RE:RE:CNN

TLT phase(II) data is to be presented at the AUA annual meeting April 28 - May1
The AUA was mentioned multiple times in the CNN article about the shortage of BCG

This is very close to the exact time the FDA has (60 days) to respond to TLT BTD application.

Might be a good time for all the shareholders to contact CNN acticle author Elizabeth Cohen about TLT.
Also Marta Wosinska the former FDA medical economist who is now with Brookings Institution might be a good person to contact. She was quiet vocal about the shortage in the article.

<< Previous

Bullboard Posts

Next >>

BriaCell to report positive cancer research at medical convention